155 related articles for article (PubMed ID: 27997511)
1. CLINICAL OUTCOMES OF INTRAVITREAL BEVACIZUMAB VERSUS PHOTODYNAMIC THERAPY WITH OR WITHOUT BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION: A 7-Year Follow-up Study.
Kang EC; Seo JG; Kim BR; Koh HJ
Retina; 2017 Sep; 37(9):1775-1783. PubMed ID: 27997511
[TBL] [Abstract][Full Text] [Related]
2. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M
Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
[TBL] [Abstract][Full Text] [Related]
3. [Intravitreal bevacizumab injections versus verteporferin photodynamic therapy for macular choroidal neovascularization in high myopia: 24-month follow-up].
El Matri L; Chebil A; Bouraoui R; Kort F; Bouladi M; Basaraih S
J Fr Ophtalmol; 2013 Jan; 36(1):29-34. PubMed ID: 23238073
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population.
El Matri L; Kort F; Chebil A; Bouraoui R; Merdassi A; Bouladi M
Graefes Arch Clin Exp Ophthalmol; 2011 Sep; 249(9):1287-93. PubMed ID: 21484465
[TBL] [Abstract][Full Text] [Related]
5. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization.
Ikuno Y; Nagai Y; Matsuda S; Arisawa A; Sho K; Oshita T; Takahashi K; Uchihori Y; Gomi F
Am J Ophthalmol; 2010 Jan; 149(1):140-6. PubMed ID: 19846061
[TBL] [Abstract][Full Text] [Related]
6. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation.
Baba T; Kubota-Taniai M; Kitahashi M; Okada K; Mitamura Y; Yamamoto S
Br J Ophthalmol; 2010 Jul; 94(7):864-70. PubMed ID: 19965833
[TBL] [Abstract][Full Text] [Related]
7. Choroidal thickness after treatment for myopic
choroidal neovascularization.
Farinha CL; Baltar AS; Nunes SG; Franqueira NF; Figueira JP; Pires IA; Cachulo ML; Silva RM
Eur J Ophthalmol; 2013; 23(6):887-98. PubMed ID: 23787449
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes.
Sarao V; Veritti D; Macor S; Lanzetta P
Graefes Arch Clin Exp Ophthalmol; 2016 Mar; 254(3):445-54. PubMed ID: 26084446
[TBL] [Abstract][Full Text] [Related]
9. Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization.
Parravano M; Ricci F; Oddone F; Missiroli F; De Felici C; Varano M
Retina; 2014 Oct; 34(10):2053-62. PubMed ID: 24946101
[TBL] [Abstract][Full Text] [Related]
10. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.
Pece A; Milani P; Monteleone C; Trombetta CJ; De Crecchio G; Fasolino G; Matranga D; Cillino S; Vadalà M
Graefes Arch Clin Exp Ophthalmol; 2015 Nov; 253(11):1867-72. PubMed ID: 25500986
[TBL] [Abstract][Full Text] [Related]
12. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A
Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy: photodynamic therapy and bevacizumab to treat myopic neovascular membranes. One-year follow-up.
Desco MC; Mataix J; Garcia-Pous M; Palacios-Pozo E; Navea A
Retina; 2011 Mar; 31(3):475-81. PubMed ID: 20966825
[TBL] [Abstract][Full Text] [Related]
14. HALF-DOSE PHOTODYNAMIC THERAPY COMBINED WITH BEVACIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Lee JH; Lee WK
Retina; 2015 Aug; 35(8):1561-8. PubMed ID: 25768248
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization.
Yoon JU; Byun YJ; Koh HJ
Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
[TBL] [Abstract][Full Text] [Related]
17. Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis.
Cionni DA; Lewis SA; Petersen MR; Foster RE; Riemann CD; Sisk RA; Hutchins RK; Miller DM
Ophthalmology; 2012 Feb; 119(2):327-32. PubMed ID: 22133795
[TBL] [Abstract][Full Text] [Related]
18. SIX-YEAR OUTCOMES OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA.
Kasahara K; Moriyama M; Morohoshi K; Yoshida T; Simada N; Nagaoka N; Yokoi T; Shinohara K; Kaneko Y; Suga M; Ohno-Matsui K
Retina; 2017 Jun; 37(6):1055-1064. PubMed ID: 27755380
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
Ikuno Y; Sayanagi K; Soga K; Sawa M; Tsujikawa M; Gomi F; Tano Y
Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.
Kang HM; Koh HJ
Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
